No Access To EMA Documents For Non-EU Entities As Requests Get Excessively Burdensome
Executive Summary
The European Medicines Agency is facing excessive workload because of high volumes of access to document requests, and has decided not to process requests coming from outside of the EU.
You may also be interested in...
Pharma firms way ahead in requesting access to EMA documents
When the European Medicines Agency was drafting its policy on the proactive publication of clinical trial data, one concern expressed by the R&D industry was that the documents released might be of benefit to competitor companies, particularly if they contained commercially confidential information.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.